Navigation Links
Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
Date:2/21/2008

SAN DIEGO, Feb. 21 /PRNewswire/ -- Accumetrics, Inc. a privately-held medical device company and maker of the VerifyNow(R) family of tests that measure patient response to antiplatelet drugs, announced today that it has raised $28.8 million in its Series D financing. The syndicate was led by Arnerich Massena & Associates, Inc. and BBT Fund, L.P. Also participating in the round were previous investors: Essex Woodland Health Ventures, RiverVest, PTV Sciences, KB Partners and Kaiser Permanente Ventures.

"We feel Accumetrics will play a major role in personalized medicine by reducing the risk of cardiovascular disease and improving patient well-being. The company is late stage; they have a patented technology platform, multiple reimbursed and FDA cleared products that provide useful information to assist physicians in their care of patients regarding antiplatelet medications. This financing also supports a major clinical trial to link individualized therapy to improved clinical outcomes," said Anthony Arnerich, President and CEO, Arnerich Massena and Associates, Inc.

Because millions of patients are prescribed Plavix(R) and aspirin to lower the risk of coronary heart disease worldwide, the need to tailor antiplatelet therapy and improve clinical outcome is significant. Under the direction of the Scripps Advanced Clinical Trials center, Accumetrics is sponsoring a 6000 patient, multi-center trial, called GRAVITAS (Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety) to establish platelet function testing with VerifyNow as the standard of care. The Executive Committee comprises a group of nationally recognized physicians in the field of cardiology and includes Matthew Price, MD (Principal Investigator), Eric Topol, MD, Paul Teirstein, MD, and Christopher Cannon, MD.

"The GRAVITAS trial, using VerifyNow to gauge patients' response is prototypic of the future of individualized medicine," said Matthew Price, MD, Director, Cardiac Catheterization Laboratory, Scripps Clinic, La Jolla, California. "Not everyone responds the same way to current anti-platelet medications, so why should we treat our patients as if they did? The results of this trial will help physicians make clinical decisions to maximize safety and improve outcomes for a large number of patients taking anti-platelet therapy."

"Completion of this $28.8 million financing enables us to initiate the GRAVITAS study and positions the company for commercial success," said Steven Frankel, CEO. "This financing is recognition of the steady progress we've made focusing on surgical procedures where platelet function testing has immediate clinical relevance and gives us an excellent foundation in the hospital setting. We believe the results of the GRAVITAS trial will establish the VerifyNow system as a routine diagnostic tool."

About Accumetrics (http://www.accumetrics.com)

Accumetrics is committed to advancing medical understanding of platelets and enhancing quality of care for patients at a risk of cardiovascular disease by providing industry-leading diagnostic tests for platelet function assessment.

VerifyNow is the first, simple and accurate system for measuring the individual response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, Plavix(R), ReoPro(R), and Integrilin(R), the VerifyNow system provides a valuable tool to help guide treatment decisions.

CONTACT: Steven Frankel, 858-404-8201, sfrankel@accumetrics.com.


'/>"/>
SOURCE Accumetrics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
2. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
3. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
4. Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin
5. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
6. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
7. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
8. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
9. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
10. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
11. Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... announces the European launch of their new low volume, high throughput ... Cambridge, U.K on October 4th. The new ... unprecedented speed and sensitivity while using far less sample volume through ... ... ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion to ... awards. Ranked as number one in the South Florida Business ... in Inc. 5000 yearly list, the national specialty pharmacy has ... Armando Bardisa will soon be honored by SFBJ as ... Set to receive his award in October, ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... Pa. (PRWEB) , ... October 13, 2017 , ... While ... dark poses a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. ... to medication in darkness or restricted lighting. As such, it eliminates the need to ...
(Date:10/13/2017)... ... 2017 , ... Lori R. Somekh, founder of the Law Office of ... elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain ... to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... ... 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at ... towards children of all ages; it is a non-competitive, non-timed event, which is all ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
Breaking Medicine News(10 mins):